Literature DB >> 23556482

Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis.

Kazuo Tarao1, Shinichi Ohkawa, Yohei Miyagi, Soichiro Morinaga, Kenji Ohshige, Naoto Yamamoto, Makoto Ueno, Satoshi Kobayashi, Ryo Kameda, Setsuo Tamai, Yoshiyasu Nakamura, Kaoru Miyakawa, Yoichi Kameda, Masahiko Okudaira.   

Abstract

OBJECTIVE: It is accepted that inflammation promotes malignant progression in the development of cancers. Whether, this is true for hepatocellular carcinoma (HCC) remains as an open question. We examined the relationship between the inflammatory histology activity index (HAI) in the background liver cirrhosis (LC) and the histological grading of the HCC in the hepatectomized HCC patients with HCV-associated LC.
MATERIAL AND METHODS: Out of 264 HCC patients who underwent curative hepatic resection, 197 had HCV-associated LC. Among them, 52 patients with a small solitary HCC nodule (< 5 cm in diameter) were studied. Inflammation in the background LC was evaluated by modified Knodell's HAI. To evaluate the inflammation, piece meal necrosis, intra lobular cellular degeneration and focal necrosis, portal cellular inflammation (0-4, each) were estimated. The average HAI was calculated. The grade of malignancy of HCC was determined by WHO classification.
RESULTS: The average HAI in the 15 patients with moderately differentiated HCC (4.3 ± 0.8, mean ± SD) was significantly larger than that in 11 patients with well differentiated HCC (3.5 ± 0.6, p = 0.036). The HAI in the 24 patients whose HCC nodules contained poorly differentiated HCC (5.2 ± 1.1) was significantly larger than that in patients with moderately differentiated HCC (p = 0.025). Thus, the HAI order was well differentiated group < moderately differentiated group < poorly differentiated group.
CONCLUSIONS: Inflammation in the background non-cancerous cirrhotic portion would evoke malignant progression in HCC development from HCV-associated LC.

Entities:  

Mesh:

Year:  2013        PMID: 23556482     DOI: 10.3109/00365521.2013.782064

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Secretome of senescent hepatoma cells modulate immune cell fate by macrophage polarization and neutrophil extracellular traps formation.

Authors:  Bijoya Sen; Savera Aggarwal; Rhisita Nath; Rashi Sehgal; Ravinder Singh; Khushboo Agrawal; Ashwini Nagaraghatta Shashidhara; Archana Rastogi; Meenu Bajpai; Viniyendra Pamecha; Nirupma Trehanpati; Gayatri Ramakrishna
Journal:  Med Oncol       Date:  2022-06-21       Impact factor: 3.064

2.  Association study of two inflammation-related polymorphisms with susceptibility to hepatocellular carcinoma: a meta-analysis.

Authors:  Jiajing Liu; Bo Xie; Shuilian Chen; Feng Jiang; Wei Meng
Journal:  BMC Med Genet       Date:  2014-08-10       Impact factor: 2.103

3.  The Deficiency of Indoleamine 2,3-Dioxygenase Aggravates the CCl4-Induced Liver Fibrosis in Mice.

Authors:  Hideyuki Ogiso; Hiroyasu Ito; Tatsuya Ando; Yuko Arioka; Ayumu Kanbe; Kazuki Ando; Tetsuya Ishikawa; Kuniaki Saito; Akira Hara; Hisataka Moriwaki; Masahito Shimizu; Mitsuru Seishima
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

4.  lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway.

Authors:  Weidong Pan; Wen Li; Jun Zhao; Zhiyi Huang; Jingyuan Zhao; Shuxian Chen; Chusi Wang; Youqiu Xue; Feng Huang; Qiannan Fang; Julie Wang; David Brand; Song Guo Zheng
Journal:  Mol Oncol       Date:  2019-08-22       Impact factor: 6.603

5.  Etiology-Specific Analysis of Hepatocellular Carcinoma Transcriptome Reveals Genetic Dysregulation in Pathways Implicated in Immunotherapy Efficacy.

Authors:  Wei Tse Li; Angela E Zou; Christine O Honda; Hao Zheng; Xiao Qi Wang; Tatiana Kisseleva; Eric Y Chang; Weg M Ongkeko
Journal:  Cancers (Basel)       Date:  2019-08-30       Impact factor: 6.639

Review 6.  Pattern recognition receptors in health and diseases.

Authors:  Danyang Li; Minghua Wu
Journal:  Signal Transduct Target Ther       Date:  2021-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.